###begin article-title 0
Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: OI HS. Performed the experiments: HS KS WK. Analyzed the data: HS. Contributed reagents/materials/analysis tools: EC OI HS. Wrote the paper: OI HS.
###end p 1
###begin p 2
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
In patients with Huntington's disease (HD), the proteolytic activity of the ubiquitin proteasome system (UPS) is reduced in the brain and other tissues. The pathological hallmark of HD is the intraneuronal nuclear protein aggregates of mutant huntingtin. We determined how to enhance UPS function and influence catalytic protein degradation and cell survival in HD. Proteasome activators involved in either the ubiquitinated or the non-ubiquitinated proteolysis were overexpressed in HD patients' skin fibroblasts or mutant huntingtin-expressing striatal neurons. Following compromise of the UPS, overexpression of the proteasome activator subunit PA28gamma, but not subunit S5a, recovered proteasome function in the HD cells. PA28gamma also improved cell viability in mutant huntingtin-expressing striatal neurons exposed to pathological stressors, such as the excitotoxin quinolinic acid and the reversible proteasome inhibitor MG132. These results demonstrate the specific functional enhancements of the UPS that can provide neuroprotection in HD cells.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 304 307 304 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Paulson1">[1]</xref>
###xml 464 467 464 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Myers1">[2]</xref>
###xml 593 596 593 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Trottier1">[3]</xref>
###xml 597 600 597 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-dePril1">[6]</xref>
###xml 858 861 858 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Coux1">[7]</xref>
###xml 863 866 863 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Layfield1">[8]</xref>
###xml 453 458 <span type="species:ncbi:9606">human</span>
Huntington's disease (HD) is an adult onset autosomal dominant inherited disease, characterized clinically by a progressive movement and psychiatric disorder. Neuropathologically, HD is associated with neuronal dysfunction and cell death, especially in the caudate-putamen (striatum) region of the brain [1]. HD is caused by mutations increasing the number of CAG repeats in exon 1 of the huntingtin gene (IT15), which is expressed in most cells of the human body [2]. A hallmark of the disease neuropathology is intracellular ubiquitin positive nuclear inclusion bodies of mutated huntingtin [3]-[6]. One potential cause for such abnormal protein aggregation is dysfunction or overloading of the ubiquitin-proteasome system (UPS), which is essential for the clearance of short-lived, mislocated, misfolded, mutated, and damaged proteins in eukaryotic cells [7], [8].
###end p 4
###begin p 5
###xml 210 213 210 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 520 523 520 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 667 670 667 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
Previously, we discovered that proteasome activities are inhibited in striatum, frontal cortex, cerebellum and substantia nigra of HD patients' brain, and also in non-brain cells such as their skin fibroblasts [9]. In HD patients, we also found increased ubiquitin expression levels, and confirmed decreased mitochondrial complex II-III (MCII-III) enzyme activities in the caudate putamen region of the brain, and decreased brain derived neurotrophic factor (BDNF) protein levels in several brain regions of HD patients [9]. These data indicated that UPS dysfunction may precipitate the critical pathology of the vulnerable medium sized spiny neurons in the striatum [9]. It is therefore of interest therapeutically to study whether improved UPS function can reduce the abnormal protein degradation and increase cell survival in HD.
###end p 5
###begin p 6
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Groll1">[10]</xref>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Groll2">[11]</xref>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Kisselev1">[12]</xref>
###xml 543 547 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Kisselev2">[13]</xref>
###xml 878 882 878 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Rechsteiner1">[14]</xref>
###xml 884 888 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-DeMartino1">[15]</xref>
How does the UPS degrade abnormal proteins? The UPS is a large multisubunit protease assembly, where protein substrates are enzymatically processed at the catalytic sites of the central core chamber of the 20S proteasome [10], [11]. Corresponding to the function of the different subunits of the catalytic core, the activities of the 20S proteasome include (1) chymotrypsin-like (after hydrophobic residues), (2) trypsin-like (after basic residues), or (3) peptidyl-glutamyl preferring hydrolytic (PGPH, after basic residues) activities [12], [13]. When the amounts of intracellular abnormal proteins are increased, this catalytic core can assemble with proteasome activators (PA). There are two types of PA: PA28 subunits for non-ubiquitinated and PA700 subunits for ubiquitinated proteolysis, which can facilitate protein substrate entry and activation of proteasome function [14], [15]. In this report, we first describe the effect of the mutant huntingtin protein on UPS function in different HD relevant cellular systems, and then demonstrate that gene transfer of the PA subunits of the UPS can enhance abnormal protein degradation leading to improved function and survival of cells in HD.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
Experimental strategy for the modification of the UPS in HD model cells
###end title 8
###begin p 9
###xml 384 387 384 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Sipione1">[16]</xref>
###xml 706 710 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Sipione1">[16]</xref>
###xml 1034 1043 1034 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g001">Figure 1A</xref>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 521 524 <span type="species:ncbi:10116">rat</span>
Since HD patients predominantly show selective cell death for medium-sized spiny neurons in caudate-putamen (striatum) in late disease stages, but not in other tissues such as skin fibroblasts, it is interesting to compare the effects of proteasome activators in HD fibroblasts with HD model striatal neurons. For the HD in vitro model systems, we chose HD patients' skin fibroblasts [9], which show UPS dysfunction but are not vulnerable to the disease process. For modeling the most vulnerable cell type in HD, we used rat embryo derived striatal neurons with inducible mutant huntingtin expression [16]. These huntingtin-inducible striatal neurons expressed mutant huntingtin based on the Tet-ON-system [16] representing an early stage of targeted vulnerable cells in HD. By comparing wild type with mutant huntingtin overexpressing striatal neurons, we addressed the question of the consequences of altered proteasome function. Finally, we overexpressed proteasome activators in the HD model cells using lentiviral gene transfer (Figure 1A), and determined UPS function and cell viabilities after exposure to HD relevant toxins.
###end p 9
###begin title 10
###xml 103 110 <span type="species:ncbi:9606">patient</span>
Overexpression of PA28gamma but not S5a can up-regulate proteasome activities in normal control and HD patient skin fibroblasts
###end title 10
###begin p 11
###xml 156 159 149 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 352 368 341 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g001">Figure 1A and 1C</xref>
###xml 553 565 538 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g001">Figure 1B&#8211;1D</xref>
###xml 724 728 709 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Deveraux1">[17]</xref>
###xml 730 734 715 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-DeMartino2">[18]</xref>
###xml 740 752 725 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s1">introduction</xref>
###xml 923 935 908 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g001">Figure 1E&#8211;1F</xref>
###xml 1298 1310 1279 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g001">Figure 1B&#8211;1G</xref>
###xml 136 143 <span type="species:ncbi:9606">patient</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
###xml 853 858 <span type="species:ncbi:9606">human</span>
###xml 902 909 <span type="species:ncbi:9606">patient</span>
###xml 1270 1278 <span type="species:ncbi:9606">patients</span>
###xml 1491 1498 <span type="species:ncbi:9606">patient</span>
In a previous study, the overexpression of PA28alpha and beta increased chymotrypsin-like and PGPH activities in control, but not in HD patient fibroblasts [9]. In contrast, overexpression of another subunit, PA28gamma, was able to significantly increase chymotrypsin-like and PGPH activities in both normal human control and HD patients' fibroblasts (Figure 1A and 1C). Nonetheless, the increase of proteasome activities in HD patients' fibroblasts was significantly smaller than those seen in normal control fibroblasts after PA28gamma gene-transfer (Figure 1B-1D). We next investigated the overexpression of the S5a subunit of PA700, which is important for the recruitment of ubiquitinated abnormal proteins into the UPS [17], [18] (see introduction). While lentiviral overexpression of S5a increased chymotrypsin-like and PGPH activities in control human skin fibroblasts, this did not occur in HD patient fibroblasts (Figure 1E-1F). In fact, S5a expression increased trypsin-like activity and marginally but significantly (p<0.05) reduced chymotrypsin-like activity in HD fibroblasts. Notably, the effects of the overexpression of PA28gamma and S5a had a larger impact on chymotrypsin and PGPH-like activities than on trypsin activity in both normal control and HD patients' fibroblast cells (Figure 1B-1G). In parallel experiments, gene-transfer of p58 (another subunit for PA700) did not significantly alter proteasome activity in either normal (109+/-18% of control, p = 0.29) or HD patient fibroblasts (112+/-16% of control, p = 0.23).
###end p 11
###begin title 12
Mutant huntingtin expressing striatal neurons show reduced proteasome activities
###end title 12
###begin p 13
###xml 150 173 150 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">control striatal neuron</italic>
###xml 248 272 248 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HD model striatal neuron</italic>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Sipione1">[16]</xref>
###xml 717 741 717 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">control striatal neurons</italic>
###xml 837 856 831 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HD striatal neurons</italic>
###xml 299 307 <span type="species:ncbi:9606">patients</span>
To study UPS modification in the more vulnerable cells, such as striatal neurons, we used inducible cell lines expressing the wild type (26CAG, CTRL, control striatal neuron) or mutant N-terminal 548 amino acid fragment of huntingtin (105CAG, Htt, HD model striatal neuron) [16]. As we showed in HD patients' fibroblasts, we also found that chymotrypsin-like, PGPH, and trypsin-like proteasome activities were relatively decreasded in HD model striatal neurons, compared to the control striatal neurons, at both pre-differentiation (Seo and Isacson, unpublished data) and the neuronal post-differentiation stage. Notably, control and HD model striatal neurons showed significantly increased proteasome activities [in control striatal neurons; chymotrypsin: 161+/-6% (p<0.05), PGPH-like: 143+/-7% (p<0.05), trypsin: 134+/-9% (p<0.05); in HD striatal neurons; chymotrypsin: 129+/-8% (p<0.05), PGPH-like: 123+/-7% (p<0.05), trypsin: 111+/-10% (p = 0.12)] compared to parental striatal cells (ST14A; without exogenous huntingtin transfection). These results demonstrate that overexpression of mutant huntingtin with expanded CAG repeats produces a major UPS dysfunction in HD model striatal neurons compared to control striatal neurons.
###end p 13
###begin title 14
Overexpression of PA28gamma but not S5a increases proteasome activities in wild type and mutant huntingtin overexpressing striatal neurons
###end title 14
###begin p 15
###xml 499 507 488 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g002">Figure 2</xref>
To provide functional and potentially therapeutic cellular models, we next performed gene transfer of several proteasome activator subunits including the PA28alpha, beta and gamma subunits, for the 20S proteasome, and the S5a and p58 subunits of PA700 for the 26S proteasome into the HD model striatal neurons. After neuronal differentiation, we determined proteasome activities and also administered toxins that have been shown to elicit HD-like pathology in control and HD model striatal neurons (Figure 2).
###end p 15
###begin p 16
###xml 78 81 78 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 809 821 783 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g003">Figure 3A&#8211;3C</xref>
###xml 973 982 943 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g002">Figure 2B</xref>
###xml 1115 1127 1085 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g003">Figure 3D&#8211;3F</xref>
###xml 60 65 <span type="species:ncbi:9606">human</span>
Similar to the previous results in a systematic analysis in human fibroblasts [9], the viral gene transduction of PA28alpha and beta subunits did not significantly alter the proteasome activities HD model striatal neurons in this study (for example, chymotrypsin activity, PA28alpha: 105+/-12%, p = 0.11, PA28beta: 115+/-15%, p = 0.21), compared to lenti-GFP transduction. The gene transduction of PA p58 subunit also did not significantly alter the proteasome activities in either control (112+/-10% of control, p = 0.18) or HD model striatal neurons (109+/-12% of control, p = 0.15) compared to lenti-GFP transduction. In contrast, PA28gamma subunit overexpression produced a marked effect on proteasome activities including trypsin-like, chymotrypsin-like and PGPH activities in HD model striatal neurons (Figure 3A-3C). In addition, PA28gamma overexpression slightly decreased huntingtin protein levels in HD model striatal neurons after administration of doxycycline (Figure 2B). In both control and HD model striatal neurons, S5a overexpression caused only minor changes in the proteasome activities tested, (Figure 3D-3F). In fact, S5a expression slightly decreased chymotrypsin-like activity in HD model striatal neurons, and PGPH activity in control striatal neurons. Nonetheless, S5a slightly increased the trypsin-like activity in HD model striatal neurons.
###end p 16
###begin title 17
PA28gamma but not S5a improves cell survival of mutant huntingtin expressing striatal neurons, which showed increased vulnerability to neuropathological toxins
###end title 17
###begin p 18
###xml 456 460 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Cory1">[19]</xref>
###xml 653 662 649 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g004">Figure 4A</xref>
###xml 992 1012 984 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g004">Figure 4A, 4B and 4D</xref>
###xml 1118 1127 1106 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g004">Figure 4C</xref>
###xml 1244 1256 1232 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g004">Figure 4E&#8211;4G</xref>
###xml 1352 1361 1340 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g004">Figure 4F</xref>
We next evaluated if overexpression of PA28gamma and S5a lead to improved cell function and increased cell survival in HD model striatal neurons. We used three different HD relevant toxic stimuli: MG132 (a reversible proteasome inhibitor), 3-NP (a mitochondrial toxin) or QA (quinolinic acid, an excitotoxin). Cell viability of differentiated control or HD model striatal neurons was examined using the MTS assay, which reflects the number of viable cells [19]. There was a dose-dependent toxicity for each toxin in control and HD model striatal neurons. HD model striatal neurons (Htt, 105CAG) showed less cell viability after toxic exposure to MG132 (Figure 4A), 3-NP (data not shown) and QA (data not shown) than control striatal neurons (CTRL, 26 CAG) in the same conditions. Notably, PA28gamma expression significantly improved cell survival of HD model striatal neurons (Htt, 105 CAG) compared to lenti-GFP transduction after MG132 proteasome inhibitor treatment and QA excitotoxicity (Figure 4A, 4B and 4D). However, PA28gamma expression did not improve cell survival after mitochondrial toxin exposure (3-NP) (Figure 4C). Overexpression of the S5a subunit did not enhance neuronal health in either control or HD model striatal neurons (Figure 4E-4G). S5a exacerbated MG132 and QA toxin effects, but did not alter the effects of 3-NP treatment (Figure 4F). These data demonstrate that overexpression of the proteasome activator subunit PA28gamma (but not S5a) can reduce HD model neuronal cell damage (and death) associated with proteasome dysfunction and excitotoxicity, but did not protect the cellular dysfunction produced by direct mitochondrial complex II toxicity.
###end p 18
###begin title 19
Discussion
###end title 19
###begin p 20
###xml 152 160 <span type="species:ncbi:9606">patients</span>
In this study, we performed viral gene transduction of proteasome activator (PA) subunits (alpha, beta, gamma for PA28 and S5a and p58 for PA700) to HD patients' and control fibroblasts and to control and HD model striatal neurons, to determine the functionality of the UPS and potential therapeutics for this disease. HD model striatal neurons with mutant huntingtin expression (105 CAG) showed reduced proteasome activity and increased vulnerability to proteasome inhibition, mitochondrial complex II inhibition, and QA excitotoxicity compared to control striatal neurons expressing wild type huntingtin (26 CAG). Specifically, PA28gamma enhanced proteasome activities and improved cell survival after proteasome inhibition (by MG132) and QA excitotoxicity, but not after mitochondrial inhibition (by 3-NP).
###end p 20
###begin p 21
###xml 179 183 179 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Yamamoto1">[20]</xref>
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Yamamoto1">[20]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-MartinAparicio1">[21]</xref>
###xml 608 612 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Demasi1">[22]</xref>
###xml 752 756 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Chai1">[23]</xref>
###xml 964 967 964 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-dePril1">[6]</xref>
###xml 1158 1162 1158 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Bae1">[24]</xref>
###xml 1259 1263 1259 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Kaytor1">[25]</xref>
###xml 1747 1750 1747 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 1943 1947 1943 1947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Xia1">[26]</xref>
###xml 2052 2056 2052 2056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Yamamoto2">[27]</xref>
###xml 2219 2222 2219 2222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Petrucelli1">[5]</xref>
###xml 2224 2228 2224 2228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Gidalevitz1">[28]</xref>
###xml 2449 2452 2449 2452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 2454 2458 2454 2458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-DiazHernandez1">[29]</xref>
###xml 2460 2464 2460 2464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Lee1">[30]</xref>
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 1703 1711 <span type="species:ncbi:9606">patients</span>
In a related study, using a conditional transgenic mouse model of HD, neuronal inclusions and HD-like symptoms were reversed when mutant huntingtin protein expression was blocked [20]. These data indicate that continuous expression of mutant huntingtin is required for the expression of HD pathology [20]. Such clearance of mutant huntingtin in neuronal cultures in HD mice depended on proteasome function given that the irreversible proteasome inhibitor lactacystin prevented the resolution of the protein aggregate [21]. Previous studies have also demonstrated that UPS inhibition decreases cell viability [22], increase polyglutamine aggregation in Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) in vitro, and alter cell morphology [23]. Mutant huntingtin overexpressing neuroblastoma cells with ubiquitin cotransfection showed increased protein aggregates and apoptic cell death, suggesting ubiquitin involvement in HD pathological cell death [6]. Overexpression of ubiquitin E3-ligase (Siah1) increased the nuclear translocation of mutant huntingtin and cytotoxicity, indicating that ubiquitin ligation is also critical in HD pathology [24]. A shorter half-life of huntingtin delayed aggregate formation, but increased cellular toxicity [25]. Therefore it appears that cell toxicity in part is caused by unprocessed mutant huntingtin protein with the extended CAG repeats. These data imply that aggregate formation itself may not be a direct cause for the cell death, but a cellular defense mechanism. In our study, the mutant huntingtin overexpressing HD model striatal neurons did not show protein aggregates even though they demonstrated UPS dysfunction, which is similar to HD patients in early disease stages (grade 0-1)[9]. These results indicate that the mutant huntingtin itself (in the pre-aggregation stage) can produce significant proteasome dysfunction in HD. Generally, cytosolic mutant proteins may be toxic[26] to cells, and so they need to be processed by the UPS or other pathways such as lysosomes and autophagy [27]. However, when the absolute amount of cytosolic mutant protein reaches a certain limit, protein aggregations occur and consequently form nuclear inclusion bodies [5], [28]. In this scenario, aggregates are not harmful per se but just by-products in the cell. Consequently, simple aggregation inhibition may not be a proper solution for abnormal protein handling in neurodegenerative diseases [9], [29], [30].
###end p 21
###begin p 22
###xml 123 126 123 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 260 263 260 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 435 438 435 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Browne1">[31]</xref>
###xml 577 581 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Ruan1">[32]</xref>
###xml 654 657 654 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 850 854 850 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Beal1">[33]</xref>
###xml 855 859 855 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Roberts1">[35]</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
###xml 521 525 <span type="species:ncbi:10090">mice</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
###xml 831 836 <span type="species:ncbi:9606">human</span>
Previously, we found significant proteasome dysfunction in the several brain regions and skin fibroblasts from HD patients [9]. However, there are likely multiple interferences by mutant huntingtin that can precipitate HD pathology in vulnerable brain regions [9]. Impaired metabolic mitochondrial complex II-III (MC II-III) energy production is also involved in the vulnerability of the neurons in caudate-putamen area of HD patients [9], [31]. Ruan et al. also found that striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to MC II-III inhibition [32]. BDNF levels are down regulated in several brain regions of HD patients [9]. Finally, by excitotoxicity, the N-methyl-D-aspartate (NMDA) receptor agonist quinolinic acid (QA) destroy medium sized spiny neuron in very similar pattern to that seen in human HD pathology [33]-[35].
###end p 22
###begin p 23
###xml 556 560 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Barton1">[36]</xref>
###xml 749 753 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Yee1">[37]</xref>
###xml 755 759 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Metere1">[38]</xref>
###xml 956 960 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Simpson1">[39]</xref>
###xml 961 965 949 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Jacquard1">[41]</xref>
###xml 1809 1813 1793 1797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Kominami1">[42]</xref>
###xml 1894 1898 1878 1882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Kominami1">[42]</xref>
###xml 1900 1904 1884 1888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Li1">[43]</xref>
###xml 2300 2303 2284 2287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Coux1">[7]</xref>
###xml 2478 2482 2462 2466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Deveraux1">[17]</xref>
###xml 2484 2488 2468 2472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Glickman1">[44]</xref>
PA28gamma overexpression in this study caused improved UPS function as assessed by known proteolytic activities of the proteasome in both HD fibroblasts and HD model striatal neurons. Critically, such PA28gamma gene transduction reduced the HD relevant toxicity produced by proteasome inhibitor (MG132), and/or excessive glutamate receptor (QA) mediated activity. However, no neuroprotection was observed after mitochondrial complex inhibition (3-NP). One potential explanation for this result is that PA28gamma is a non-ATP dependent regulator of the UPS [36], and therefore less connected to alterations of mitochondrial metabolism. Given that QA and NMDA induced cell death is preceeded by large increases in misfolded and ubiquitinated proteins [37], [38], the observed neuroprotection against both MG132 and QA is understandable. Whereas mitocondrial toxicity decreases the threshold for NMDA mediated toxicity to increase calcium influx to the cells [39]-[41], there is no evidence that NMDA receptor impairs mitochondrial function. The consequence of such analysis is that PA28gamma could contribute to reductions in both excitotoxicity and protein toxicity whereas protection against the mitochondrial dysfunction would require an additional type of intervention. Proteasome activators of the UPS modulate different proteolytic enzyme activities by several mechanisms. This is due to the different alterations of protein structure by which the PA28 and PA700 regulators bind to the 20S proteasome core to help peptide substrates reach the catalytic core beta subunits. For example, PA28g and S5a are participating in two different major protein degradation pathways in the UPS: PA28g is involved in non-ubiquitinated protein degradation, while S5a is associated with ubiquitinated protein degradation [42]. PA28g is predominantly located in the nucleus, while S5a exists in the cytosol [42], [43]. Curiously, in our experiment, S5a overexpression decreased cell survival in the response to MG132 and QA in HD model striatal neurons. Perhaps the overexpression of S5a (one out of nine subunits complex of PA700) is not sufficient to accomplish functional effects. Alternatively, it could be a stoichiometric problem, in which there is unbalanced competition to form the 26S proteasome complex [7]. Yet another problem with excess amounts of free S5a may be the inhibition of proteasome degradation by sequestering polyubiqutinated substrates from reaching the proteasome [17], [44].
###end p 23
###begin p 24
###xml 186 190 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Bett1">[45]</xref>
###xml 394 403 382 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">increased</italic>
###xml 442 446 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo2">[46]</xref>
###xml 546 549 534 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 706 710 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo2">[46]</xref>
###xml 961 965 949 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Hansson1">[47]</xref>
###xml 1084 1088 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Bett1">[45]</xref>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 510 518 <span type="species:ncbi:9606">patients</span>
###xml 563 578 <span type="species:ncbi:10090">transgenic mice</span>
###xml 630 645 <span type="species:ncbi:10090">transgenic mice</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
###xml 746 761 <span type="species:ncbi:10090">transgenic mice</span>
###xml 864 879 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1079 1083 <span type="species:ncbi:10090">mice</span>
It was recently reported that genetic reduction of PA28gamma (also denoted REGgamma) did not alter the pathological phenotype or inclusion body formation in the striatum of R6/2 HD mice [45]. We think this absence of neuroprotection by PA28gamma compared to our positive findings can be explained by differences of experimental approaches and HD models used. For example, R6/2 mice always show increased proteasome activities in the striatum [46], which therefore does not model the UPS dysfunction seen in HD patients' brains and HD fibroblasts [9]. However, HD transgenic mice with full-size mutant huntingtin expression (YAC72 transgenic mice) do show UPS inhibition resembling that seen in HD patients [46]. This at least indicates that R6/2 transgenic mice do not model mature HD pathology due to abnormal protein processing in the UPS. Moreover, the HD R6/2 transgenic mice also completely lack QA-induced striatal excitotoxicity in modeling HD pathology [47]. Consequently, the lack of additional HD pathology by knock out of PA28gamma function during development of R6/2 mice [45] may not represent a challenge to our findings of neuroprotective effects by PAlpha28gamma enhanced UPS function.
###end p 24
###begin p 25
###xml 331 334 331 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
In summary, these results demonstrate a role of mutant huntingtin in protein toxicity and specifically provide therapeutic targets and candidates for gene transfer to enhance proteasome function. Although proteasome dysfunction is probably only one of multiple factors involved in the dynamic and progressive disease process of HD [9], our data at least demonstrate that proteasome activators are relevant candidates for future comprehensive and effective treatment approaches to HD.
###end p 25
###begin title 26
Materials and Methods
###end title 26
###begin title 27
Experimental Design
###end title 27
###begin p 28
###xml 391 400 380 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g001">Figure 1A</xref>
###xml 453 457 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Sipione1">[16]</xref>
###xml 459 467 448 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g002">Figure 2</xref>
###xml 229 236 <span type="species:ncbi:9606">patient</span>
In the experiments, we performed gene transfer of several proteasome activator subunits including PA28alpha, beta and gamma, for the 20S proteasome, and S5a and p58 subunits of the PA700 for the 26S proteasome into normal and HD patient's skin fibroblasts, and control and HD model striatal cells. After determination of the expression of the transduced genes using RT-PCR and Western blot (Figure 1A), cells were differentiated as previously described [16] (Figure 2). Cell cultured medium was collected for MTS cytotoxicity test and cells were harvested for proteasome activity determination. In addition, we administered HD relevant toxins at various concentrations for 24 hours for cytotoxicity study.
###end p 28
###begin title 29
Construction of Lentiviral Vectors and Lentiviral Transduction of proteasome activators, PA28gamma and S5a
###end title 29
###begin p 30
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Zufferey1">[48]</xref>
###xml 247 251 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Rechsteiner1">[14]</xref>
###xml 253 257 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Li1">[43]</xref>
###xml 274 278 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Kominami1">[42]</xref>
###xml 567 570 548 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
The lentivirus vector system used in our studies was kindly provided by Drs R. Zufferey and D. Trono, University of Geneva, Switzerland [48]. The PA28alpha, beta, gamma p58 and S5a cDNAs were kindly provided by Dr. Rechsteiner (University of Utah [14], [43]) and Dr. Tanaka [42], and cloned into pRRL.cPPT.PGK.GFP.W.Sin-18 (Lenti-eGFP) replacing the eGFP with the PA28gamma or S5a genes. Fibroblasts and striatal cells were transduced with Lenti-eGFP as a transduction control, PA28gamma or S5a at a multiplicity of infection (MOI) of 5 to 20 as previously described [9].
###end p 30
###begin title 31
Cell Culture
###end title 31
###begin p 32
###xml 99 102 99 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
###xml 496 500 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Sipione1">[16]</xref>
###xml 502 506 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Rigamonti1">[49]</xref>
###xml 660 669 644 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000238-g002">Figure 2B</xref>
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 240 246 <span type="species:ncbi:9913">bovine</span>
Normal and HD human fibroblasts used in this study were obtained from the Coriell Cell Repository ([9] GM08399, GM04689, GM04732). Fibroblasts were cultured in minimum essential medium (MEM; Gibco, Carlsbad, CA) supplemented with 15% fetal bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine (Gibco), 0.1 mM nonessential amino acids (Gibco), penicillin and streptomycin. Huntingtin inducible striatal cells were cultured at 37degreesC and 33degreesC in DMEM, supplemented as described previously [16], [49]. The expression levels of huntingtin protein were determined after administration of doxycycline (1 microg/ml) for 24 hours using Western blot analysis (Figure 2B).
###end p 32
###begin p 33
MG132 (Calbiochem), 3-NP (Sigma), QA (Sigma) were used at the indicated concentrations in the cell cultures. After 24 hours of treatment, medium was collected to determine cell viability by a quantitative colorimetric assay, the modified MTS assay (Promega). Harvested cells were lysed in 50 mM Tris pH8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10 microg/mL aprotinin, 25 microg/mL Leupeptin, 10 microg/mL Pepstatin, 1 mM PMSF; all protease inhibitors purchased from Sigma). Homogenates were centrifuged at 14,000x g for 30 min at 4degreesC. The protein levels were determined using the Bio-Rad Protein Assay (BIO-RAD, Hercules, CA). Samples containing equal amounts of total protein were used for the determination of proteasome activities and Western blots.
###end p 33
###begin title 34
Reverse-transcriptase (RT) PCR for transfered gene validation
###end title 34
###begin p 35
###xml 222 224 213 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 707 710 685 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 526 531 <span type="species:ncbi:9606">Human</span>
RNA samples were extracted from harvested cells using Tri Reagent (Sigma, St. Louis) and were reverse transcribed into cDNA using the Superscripttrade mark reverse transcriptase kit (Invitrogen, Carlsbad, CA) and oligo(dT)20 as primers. Reverse transcriptase reaction were carried out at 50degreesC, for 50 min. Synthesized cDNA template were amplified with forward primers for S5a (5'-ATCTATGGAAGAGCAGCGG-3') and PA28 gamma (5'-GGGTACAGCTCCTGATTCC-3') and the virus backbone reverse primer, WPRE (5'-AGCAGCGTATCCACATAGC-3'). Human beta-actin primers (forward: 5'-GGCGGCAACACCATGTACCCT-3'; reverse: 5'-AGGGGCCGGACTCGTCATACT-3') were used to determine cellular RNA expression level. PCR was performed with G-Taq DNA polymerase (Labopass, Seoul, Korea) with a denaturing step for 2 min at 94degreesC, followed by 40 cycles of 1min at 94degreesC, 1 min at 58degreesC, and 2 min at 72degreesC, and terminated by an elongation step at 72degreesC for 7 min. PCR products were visualized in 1% agarose gel electrophoresis.
###end p 35
###begin title 36
Determination of proteasomal function
###end title 36
###begin p 37
###xml 250 254 250 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Kisselev2">[13]</xref>
###xml 571 575 571 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Craiu1">[50]</xref>
Using synthetic peptides, three different proteolytic activities were measured to detect proteasome activities: (1) chymotrypsin-like (after hydrophobic residue), (2) trypsin-like (after basic residues), or (3) PGPH (after basic residues) activities [13]. These different catalytic activities are due to the function of different subunits of the catalytic core. In this study, proteasome function was determined by continuously measuring the fluorescence of 7-amido-4-methylcoumarin (AMC) (excitation 380 nm, emission 460 nm) generated from peptide-AMC linked substrates [50]. Reactions were conducted in a final volume of 200 microl containing 50 mM Tris-HCl buffer (pH 7.5) and 1 mM EDTA. After adding samples to the reaction mixtures, reactions were initiated by the following substrates: Suc-Leu-Leu-Val-Try-AMC (65 microM) for chymotrypsin activity, Z-Leu-Leu-Glu-AMC (75 microM) for PGPH activity and Boc-Leu-Arg-Arg-AMC (71 microM) for trypsin-like activity. Reactions were followed for 240 min at 25degreesC and enzymatic activities were expressed as fluorescence units (FU)/min/mg protein.
###end p 37
###begin title 38
Western blot
###end title 38
###begin p 39
###xml 118 121 118 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Seo1">[9]</xref>
The protein expression levels were determined from the cell extract using specific antibodies as previously described [9]: PA28gamma (Calbiochem 1:2,500), S5a (Calbiochem, 1:1,000), huntingtin (Chemicon, 1:5,000). Quantification of immunoreactive bands was performed using densitometry. The results were confirmed by duplicate measurements of the same samples.
###end p 39
###begin title 40
Statistical analysis
###end title 40
###begin p 41
###xml 231 237 <span type="species:ncbi:9103">Turkey</span>
All statistical analyses were carried out using JMP (version 3.1.6, SAS Institute). Data were objectively compared between different groups at different stages of disease using unpaired Student's t test and 2-way ANOVA followed by Turkey-Kramer posthoc analysis.
###end p 41
###begin p 42
We thank Dr. Rechsteiner and Dr. Tanaka for providing cDNA for proteasome activator subunits. We also thank G. Brunlid and J. Gilmartin for technical assistance.
###end p 42
###begin title 43
References
###end title 43
###begin article-title 44
Trinucleotide repeats in neurogenetic disorders.
###end article-title 44
###begin article-title 45
Huntington's disease genetics.
###end article-title 45
###begin article-title 46
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form.
###end article-title 46
###begin article-title 47
Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.
###end article-title 47
###begin article-title 48
Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system.
###end article-title 48
###begin article-title 49
Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
###end article-title 49
###begin article-title 50
Structure and functions of the 20S and 26S proteasomes.
###end article-title 50
###begin article-title 51
The ubiquitin-proteasome system and neurodegenerative disorders.
###end article-title 51
###begin article-title 52
Generalized brain and skin proteasome inhibition in Huntington's disease.
###end article-title 52
###begin article-title 53
###xml 57 62 <span type="species:ncbi:4932">yeast</span>
Purification, crystallization, and X-ray analysis of the yeast 20S proteasome.
###end article-title 53
###begin article-title 54
A gated channel into the proteasome core particle.
###end article-title 54
###begin article-title 55
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.
###end article-title 55
###begin article-title 56
The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.
###end article-title 56
###begin article-title 57
The proteasome activator 11 S REG (PA28) and class I antigen presentation.
###end article-title 57
###begin article-title 58
The proteasome, a novel protease regulated by multiple mechanisms.
###end article-title 58
###begin article-title 59
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses.
###end article-title 59
###begin article-title 60
###xml 52 63 <span type="species:ncbi:3702">Arabidopsis</span>
Inhibition of ubiquitin-mediated proteolysis by the Arabidopsis 26 S protease subunit S5a.
###end article-title 60
###begin article-title 61
PA700, an ATP-dependent activator of the 20 S proteasome, is an ATPase containing multiple members of a nucleotide-binding protein family.
###end article-title 61
###begin article-title 62
Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture.
###end article-title 62
###begin article-title 63
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.
###end article-title 63
###begin article-title 64
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.
###end article-title 64
###begin article-title 65
Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen-dependent mechanism.
###end article-title 65
###begin article-title 66
Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
###end article-title 66
###begin article-title 67
Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH.
###end article-title 67
###begin article-title 68
Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity.
###end article-title 68
###begin article-title 69
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.
###end article-title 69
###begin article-title 70
Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway.
###end article-title 70
###begin article-title 71
Progressive disruption of cellular protein folding in models of polyglutamine diseases.
###end article-title 71
###begin article-title 72
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
###xml 111 116 <span type="species:ncbi:9606">human</span>
Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.
###end article-title 72
###begin article-title 73
Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases?
###end article-title 73
###begin article-title 74
Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.
###end article-title 74
###begin article-title 75
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway.
###end article-title 75
###begin article-title 76
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.
###end article-title 76
###begin article-title 77
###xml 69 73 <span type="species:ncbi:10116">rats</span>
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
###end article-title 77
###begin article-title 78
###xml 75 78 <span type="species:ncbi:10116">rat</span>
Short- and long-term survival of large neurons in the excitotoxic lesioned rat caudate nucleus: a light and electron microscopic study.
###end article-title 78
###begin article-title 79
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Immune defects in 28-kDa proteasome activator gamma-deficient mice.
###end article-title 79
###begin article-title 80
Relationships between stress protein induction and NMDA-mediated neuronal death in the entorhinal cortex.
###end article-title 80
###begin article-title 81
###xml 64 67 <span type="species:ncbi:10116">rat</span>
Quinolinic acid modulates the activity of src family kinases in rat striatum: in vivo and in vitro studies.
###end article-title 81
###begin article-title 82
Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum.
###end article-title 82
###begin article-title 83
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.
###end article-title 83
###begin article-title 84
Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation.
###end article-title 84
###begin article-title 85
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 55 60 <span type="species:ncbi:9606">human</span>
Yeast counterparts of subunits S5a and p58 (S3) of the human 26S proteasome are encoded by two multicopy suppressors of nin1-1.
###end article-title 85
###begin article-title 86
Molecular dissection of the 11S REG (PA28) proteasome activators.
###end article-title 86
###begin article-title 87
The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.
###end article-title 87
###begin article-title 88
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
###end article-title 88
###begin article-title 89
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 120 135 <span type="species:ncbi:10090">transgenic mice</span>
Generalized ubiquitin proteasome inhibitiion in Huntington's disease patients' brains is modeled in some but not all HD transgenic mice.
###end article-title 89
###begin article-title 90
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
###end article-title 90
###begin article-title 91
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.
###end article-title 91
###begin article-title 92
Wild-type huntingtin protects from apoptosis upstream of caspase-3.
###end article-title 92
###begin article-title 93
Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation.
###end article-title 93
###begin title 94
Figures and Tables
###end title 94
###begin p 95
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 973 981 <span type="species:ncbi:9606">patients</span>
Proteasome activities following lentiviral gene transfer of PA28gamma and S5a, in control and HD fibroblasts. (A) Expression levels of gene and protein of S5a and PA28gamma were determined using RT-PCR and Western blot after viral gene transfer to HD fibroblasts (lane 1 and 3; lenti-GFP transduced cells, lane 2; S5a transduced cells, and lane 4; PA28gamma transduced cells). (B-G) Proteasome activities were increased by lentiviral gene transduction of PA28gamma. Chymotrypsin-like (B, E), PGPH (C, F) and trypsin-like (D, G) activities were detected in normal control (<36 CAG) and HD patients' skin fibroblasts, which overexpress PA28gamma (B-D) or S5a (E-G). The overexpression of PA28gamma increased chymotrypsin and PGPH-like, but not trypsin proteasome activities in both normal control and HD fibroblasts compared to lenti-GFP transduction. Chymotrypsin activities and PGPH activities were increased in control fibroblasts by overexpression of S5a. However, in HD patients' fibroblasts, S5a did not increase PGPH activities and slightly decreased chymotrypsin-like activities (section sign, p<0.05 between control and HD fibroblasts. *, p<0.05 between the gene transferred groups of control protein GFP and PA28gamma or S5a). The experiments were repeated three times in triplicate.
###end p 95
###begin p 96
Lentiviral gene transfer of PA28gamma and S5a, in control and HD model striatal neurons. (A) Schematic experimental outline of gene transfer and differentiation of striatal neurons followed by exposure to HD model experimental toxins. HD model striatal cells were gene engineered with PA28gamma, S5a. After verification of expression for the transferred genes, cells were grown in medium containing 1mug/ml of doxycyclin for 48h before toxin treatment. After 24 h incubation in the toxic environment, medium was collected for the MTS assay and cells were harvested for proteasome activity determination. (B) Semiquantitative Western blot of the huntingtin showing a slight decrease of protein levels by lenti-viral transduction of PA28gamma gene into HD model striatal cells. Results are shown as percentage of levels of lenti-GFP control group (* p<0.05).
###end p 96
###begin p 97
###xml 376 380 372 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000238-Sipione1">[16]</xref>
Proteasome activities following lentiviral gene transfer of PA28gamma and S5a, in control and HD model striatal neurons. (A-F) Chymotrypsin-like (A, D), PGPH (B, E) and trypsin-like (C, F) activities were detected. Both wild type (CTRL, 26 CAG, control striatal neurons) and mutant huntingtin overexpressing HD model striatal neurons (Htt, 105 CAG, HD model striatal neurons) [16] were transduced with PA28gamma or S5a. Basal proteasome activities were decreased in HD model striatal neurons compared to control cells with normal range of CAG repeats. However, the overexpression of PA28gamma increased proteasome activities in both control and HD model striatal neurons. The overexpression of S5a decreased chymotrypsin-like activities in HD model striatal neurons and decreased PGPH activities in control striatal neurons. In contrast, total trypsin-like activities were slightly increased in both control and HD model striatal neurons after the gene transfer of S5a (section sign, p<0.05 between control and HD striatal neurons. *, p<0.05 between the gene transferred groups of control protein GFP and PA28gamma or S5a). The experiments were repeated three times in triplicate.
###end p 97
###begin p 98
Experimental exposure of PA28gamma (A-D) or S5a (E-G) overexpressing control and HD model striatal neurons to toxin modeling pathophysiological processes observed in HD. (A) MG132 treated control (CTRL, 26 CAG) and HD model striatal neurons (Htt, 105 CAG) transduced with PA28gamma. Shown are cell viabilities after 24 hours of exposure to MG132. (B-G) The reversible proteasome inhibitor, MG132 (B, E); the mitochondrial inhibitor, 3-NP (C, F); and the excitotoxin, QA (D, G) were used at various concentrations to treat control and HD model striatal neurons. HD model striatal neurons showed significantly decreased the resistance to those neuropathological toxins compared to control striatal neurons. PA28gamma significantly improved cell survival, and S5a significantly decreased cell survival after exposure to MG132 and QA, but not 3-NP, respectively (section sign, p<0.05 between wild-type and mutant huntingtin overexpressing striatal neurons. *, p<0.05 between the gene transferred groups of control protein GFP and PA28gamma or S5a). The experiments were repeated three times in triplicate.
###end p 98
###begin p 99
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 99
###begin p 100
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was primarily supported by NIH NS-30064 (to OI), the Vaughan Foundation (to OI), and in part by a KRF Grant funded by the Korean Government (MOEHRD) (KRF-2005-202-C00230) (to HS), Hanyang University (HY-2005) (to HS) and BK21 fellowship (to WK).
###end p 100

